AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:12:00Z
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 220332.00M | 126268.00M | 143018.00M | 158516.00M | 170343.00M |
| Minority interest | 469.00M | 746.00M | 18442.00M | 51.00M | 4400.00M |
| Net income | 184965.00M | 114185.00M | 111858.00M | 122193.00M | 132759.00M |
| Selling general administrative | 97775.00M | 91771.00M | 91902.00M | 95094.00M | 85217.00M |
| Selling and marketing expenses | 7519.00M | 9981.00M | 13044.00M | 15406.00M | 16761.00M |
| Gross profit | 364438.00M | 279723.00M | 244654.00M | 276589.00M | 308841.00M |
| Reconciled depreciation | 17165.00M | 16351.00M | 14779.00M | 14115.00M | 19199.00M |
| Ebit | 224832.00M | 127109.00M | 143959.00M | 161132.00M | 169043.00M |
| Ebitda | 241997.00M | 143460.00M | 158738.00M | 175247.00M | 188242.00M |
| Depreciation and amortization | 17165.00M | 16351.00M | 14779.00M | 14115.00M | 19199.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 149003.00M | 110312.00M | 117438.00M | 130628.00M | 138537.00M |
| Other operating expenses | 277679.00M | 224825.00M | 179737.00M | 202740.00M | 225183.00M |
| Interest expense | 4500.00M | 841.00M | 941.00M | 2616.00M | 581.00M |
| Tax provision | 35836.00M | 12829.00M | 30956.00M | 36322.00M | 37037.00M |
| Interest income | 75829.00M | 16797.00M | 26522.00M | 30504.00M | 2393.00M |
| Net interest income | 71329.00M | 15956.00M | 25581.00M | 27888.00M | 1812.00M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 35836.00M | 12829.00M | 30956.00M | 36322.00M | 37037.00M |
| Total revenue | 426684.00M | 335138.00M | 297177.00M | 333371.00M | 363721.00M |
| Total operating expenses | 215433.00M | 169410.00M | 127214.00M | 145958.00M | 170303.00M |
| Cost of revenue | 62246.00M | 55415.00M | 52523.00M | 56782.00M | 54880.00M |
| Total other income expense net | 61084.00M | 15601.00M | 50186.00M | 31133.00M | 31805.00M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 184496.00M | 113439.00M | 112062.00M | 122194.00M | 133306.00M |
| Net income applicable to common shares | - | 114185.00M | 111858.00M | 122193.00M | 132759.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 1311800.00M | 1150601.00M | 998992.00M | 871526.00M | 778741.00M |
| Intangible assets | 96309.00M | 81223.00M | 76558.00M | 46536.00M | 35511.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 53076.00M | 25120.00M | 21700.00M | 22194.00M | 28902.00M |
| Total liab | 189922.00M | 157316.00M | 134442.00M | 106915.00M | 106314.00M |
| Total stockholder equity | 1100046.00M | 975661.00M | 846108.00M | 764560.00M | 668027.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 69596.00M | 65079.00M | 37483.00M | 27552.00M | 32223.00M |
| Common stock | 21279.00M | 21279.00M | 21279.00M | 21279.00M | 21279.00M |
| Capital stock | 21279.00M | 21279.00M | 21279.00M | 21279.00M | 21279.00M |
| Retained earnings | 940606.00M | 832958.00M | 752248.00M | 708291.00M | 639461.00M |
| Other liab | - | 29191.00M | 29654.00M | 21005.00M | 17206.00M |
| Good will | 9819.00M | 9638.00M | 9357.00M | 10854.00M | 19258.00M |
| Other assets | 1.00M | 12912.00M | 11733.00M | 3052.00M | 4.00M |
| Cash | 309224.00M | 254420.00M | 276173.00M | 208861.00M | 193549.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 158552.00M | 124396.00M | 100180.00M | 81119.00M | 89107.00M |
| Current deferred revenue | 71937.00M | 40000.00M | 49416.00M | 39443.00M | 46522.00M |
| Net debt | -299813.00000M | -247746.00000M | -268186.00000M | -200709.00000M | -192629.00000M |
| Short term debt | 3014.00M | 2945.00M | 3379.00M | 3361.00M | 920.00M |
| Short long term debt | - | - | - | - | 920.00M |
| Short long term debt total | 9411.00M | 6674.00M | 7987.00M | 8152.00M | 920.00M |
| Other stockholder equity | -961885.00000M | -854237.00000M | -773527.00000M | -729570.00000M | -660740.00000M |
| Property plant equipment | - | 112417.00M | 95710.00M | 76007.00M | 74653.00M |
| Total current assets | 784192.00M | 659205.00M | 556238.00M | 516026.00M | 461743.00M |
| Long term investments | - | - | - | - | 185782.00M |
| Net tangible assets | - | 884800.00M | 760193.00M | 707170.00M | 613259.00M |
| Short term investments | 254131.00M | 210757.00M | 142151.00M | 171157.00M | 133264.00M |
| Net receivables | 109842.00M | 123016.00M | 78211.00M | 79996.00M | 65918.00M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | 57919.00M | 45892.00M | 38003.00M | 33818.00M | 40110.00M |
| Accounts payable | 14005.00M | 16372.00M | 9902.00M | 10763.00M | 9442.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 3.00M | 5.00M | 4.00M | 4.00M | -2.00000M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 527607.00M | 491396.00M | 442754.00M | 355500.00M | 316994.00M |
| Capital lease obligations | 9411.00M | 6674.00M | 7987.00M | 8152.00M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -48292.00000M | -65580.00000M | 35015.00M | -6300.00000M | -23825.00000M |
| Change to liabilities | 0.00000M | 11686.00M | -2380.00000M | -5747.00000M | 4969.00M |
| Total cashflows from investing activities | - | -96204.00000M | -5261.00000M | -29144.00000M | -36349.00000M |
| Net borrowings | - | -3453.00000M | -3648.00000M | -3648.00000M | -10000.00000M |
| Total cash from financing activities | -84123.00000M | -36615.00000M | -43891.00000M | -88174.00000M | -87011.00000M |
| Change to operating activities | - | 15087.00M | -16524.00000M | -9202.00000M | 801.00M |
| Net income | 220332.00M | 126268.00M | 143018.00M | 158516.00M | 170343.00M |
| Change in cash | 54804.00M | -21753.00000M | 67312.00M | 13061.00M | 23400.00M |
| Begin period cash flow | 254420.00M | 276173.00M | 208861.00M | 195800.00M | 172400.00M |
| End period cash flow | 309224.00M | 254420.00M | 276173.00M | 208861.00M | 195800.00M |
| Total cash from operating activities | 177867.00M | 102068.00M | 109039.00M | 131940.00M | 145684.00M |
| Issuance of capital stock | - | 0.00000M | 33534.00M | - | - |
| Depreciation | 17165.00M | 16351.00M | 14779.00M | 14115.00M | 19199.00M |
| Other cashflows from investing activities | - | 940.00M | -3741.00000M | -5726.00000M | -1918.00000M |
| Dividends paid | -36142.00000M | -33146.00000M | -32529.00000M | -31122.00000M | 27639.00M |
| Change to inventory | -11699.00000M | -7133.00000M | -3435.00000M | 1158.00M | -4832.00000M |
| Change to account receivables | 13941.00M | -43417.00000M | 2993.00M | 21371.00M | -12430.00000M |
| Sale purchase of stock | -49539.00000M | -14.00000M | -50134.00000M | -50159.00000M | -50270.00000M |
| Other cashflows from financing activities | 1558.00M | -3455.00000M | 8886.00M | -6893.00000M | 898.00M |
| Change to netincome | -37365.00000M | -16774.00000M | -29412.00000M | -48271.00000M | -32366.00000M |
| Capital expenditures | 37187.00M | 31564.00M | 32944.00M | 11768.00M | 9124.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | 9980.00M | -38864.00000M | -2822.00000M | 16782.00M | -11772.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -69610.00000M | -1687.00000M | -45936.00000M | -57473.00000M | -32086.00000M |
| Free cash flow | 140680.00M | 70504.00M | 76095.00M | 120172.00M | 136560.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SGIOY Shionogi & Co Ltd ADR |
0.02 0.29% | 6.89 | 9.17 | 14.64 | 0.03 | 1.66 | 0.02 | 0.04 |
| ZTS Zoetis Inc |
-2.975 1.78% | 164.03 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.12 0.42% | 28.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-1.925 1.33% | 142.50 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.07 0.53% | 13.04 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
1-8, Doshomachi 3-chome, Osaka, Japan, 541-0045
| Name | Title | Year Born |
|---|---|---|
| Dr. Isao Teshirogi Ph.D. | Chairman, CEO & Pres | 1959 |
| Susumu Mitsumori | VP of Fin. & Accounting Department | NA |
| Mr. Kazuhiro Hatanaka | Sr. Exec. Officer & Sr. VP of Admin. Division | NA |
| Mr. Takeshi Shiota Ph.D. | Corp. Officer and Sr. VP of Corp. Quality Assurance, Ethics & Compliance Management Div. | NA |
| Mr. Yoshimasa Kyokawa | VP of Corp. Communications & Sec. Office | NA |
| Yoshihiro Furuya | VP of Gen. Marketing and Compliance Officer of Corp. GXP Compliance Office | NA |
| Mr. Kohji Hanasaki Ph.D. | Sr. Exec. Officer and Sr. VP of Supply Supervisory Unit & Global Bus. Division | NA |
| Dr. John A. Keller Ph.D. | Sr. Exec. Officer and Sr. VP of R&D Supervisory Unit | 1965 |
| Akira Kato Ph.D. | Corp. Officer & Pres of Shionogi Pharma Co., Ltd | NA |
| Dr. Ryuichi Kiyama Ph.D. | Sr. Exec. Officer & Sr. VP of Corp. Strategy Division | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...